Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade A 29.61 2.03% 0.59
ACAD closed up 2.03 percent on Friday, August 16, 2019, on 77 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ACAD trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Wide Bands Range Expansion 2.03%
Overbought Stochastic Strength 2.03%
Down 3 Days in a Row Weakness 2.03%
Down 4 Days in a Row Weakness 2.03%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.68%
Doji - Bullish? Reversal 1.68%
Wide Bands Range Expansion 1.68%
Overbought Stochastic Strength 1.68%

Older signals for ACAD ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Chemistry Health Biopharmaceutical Pharmaceutical Industry Chemical Compounds Medication Alzheimer's Disease Parkinson's Disease Schizophrenia Glaucoma Neurological Disorders Chronic Pain Treatment Of Parkinson's Disease Treatment Of Alzheimer's Disease Treatment Of Glaucoma Allergan
Is ACAD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 30.38
52 Week Low 12.86
Average Volume 1,358,246
200-Day Moving Average 23.6141
50-Day Moving Average 26.544
20-Day Moving Average 27.046
10-Day Moving Average 29.263
Average True Range 1.1906
ADX 25.42
+DI 25.4835
-DI 15.3609
Chandelier Exit (Long, 3 ATRs ) 26.8082
Chandelier Exit (Short, 3 ATRs ) 25.1318
Upper Bollinger Band 32.4978
Lower Bollinger Band 21.5942
Percent B (%b) 0.74
BandWidth 40.315019
MACD Line 1.0344
MACD Signal Line 0.8202
MACD Histogram 0.2142
Fundamentals Value
Market Cap 3.63 Billion
Num Shares 122 Million
EPS -2.53
Price-to-Earnings (P/E) Ratio -11.70
Price-to-Sales 67.33
Price-to-Book 10.21
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.57
Resistance 3 (R3) 30.55 30.20 30.41
Resistance 2 (R2) 30.20 29.96 30.22 30.36
Resistance 1 (R1) 29.91 29.81 30.06 29.93 30.30
Pivot Point 29.56 29.56 29.64 29.58 29.56
Support 1 (S1) 29.27 29.32 29.42 29.29 28.92
Support 2 (S2) 28.92 29.17 28.94 28.86
Support 3 (S3) 28.63 28.92 28.81
Support 4 (S4) 28.65